Topic starter
There is a new scientific article which is mainly about smarter and safer ways to administer psychedelics so that their therapeutic effects can potentially be better utilised.
In it, we discuss:
Psychedelics such as psilocybin, LSD, DMT and MDMA seem to be of interest in conditions such as depression, PTSD and addiction. According to the authors, they do so mainly through processes in the brain associated with neuroplasticity, i.e. the brain's ability to adapt and make new connections.
The real focus of this article is not so much on new therapy results, but on how to deliver these substances more intelligently. For example, they describe systems such as nanoparticles, liposomes and other carriers that can ensure that a drug gets into the body or brain in a more targeted way and possibly causes fewer side effects.
The authors also mention new ways of administration, such as through the nose or through the skin, and link this to more precise dosing and possibly better compliance. So the idea is: don't just look what do psychedelics, but also how you can technically deliver them better.
Importantly, however, based on the PubMed summary, this appears to be mainly a review of opportunities and innovations, and not a clinical trial proving that these new forms of administration are already working better in patients. All theories have yet to be tested.
In one sentence, this article is mainly about smarter and safer ways to administer psychedelics, so that their therapeutic effects can potentially be better utilised.
Spoiler
New article description
Abstract
Psychedelic compounds such as psilocybin, Lysergic Acid Diethylamide (LSD), N,Ndimethyltryptamine (DMT), and 3,4-methylenedioxymethamphetamine (MDMA) are emerging as novel therapeutics for neuropsychiatric disorders, including depression, Post-Traumatic Stress Disorder (PTSD), and addiction. Acting primarily through serotonin 5-HT2A receptor agonism, they activate intracellular cascades involving Brain-Derived Neurotrophic Factor (BDNF), Tropomyosin receptor kinase B (TrkB), and the mammalian target of rapamycin (mTOR) pathway, leading to enhanced neuroplasticity and synaptogenesis. Recent evidence demonstrates direct TrkB binding and sustained cortical remodelling, underlying their rapid and durable antidepressant effects. Advanced Drug Delivery Systems (DDS)-including liposomes, Solid Lipid Nanoparticles (SLNs), and Poly(lactic-co-glycolic acid) (PLGA) carriers-are being engineered to achieve controlled, braintargeted, and stimuli-responsive release while minimising systemic toxicity. Integration with microfluidic fabrication, Artificial Intelligence (AI)-based dosing, and non-invasive routes such as intranasal and transdermal delivery improves precision and patient adherence. By merging neuropharmacology with materials science, these innovations are redefining psychedelic-assisted therapy through enhanced safety, personalised dosing, and translational potential for central nervous system disorders.
Keywords: Psychedelic drug delivery; blood-brain barrier; controlled-release systems; nanoparticles; neuroplasticity; psilocybin.
Posted : 18 March 2026 14:16